nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC22A3—Lamivudine—acquired immunodeficiency syndrome	0.213	0.306	CbGbCtD
Methamphetamine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0663	0.0949	CbGbCtD
Methamphetamine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0623	0.0892	CbGbCtD
Methamphetamine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0623	0.0892	CbGbCtD
Methamphetamine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0564	0.0807	CbGbCtD
Methamphetamine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0564	0.0807	CbGbCtD
Methamphetamine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0487	0.0697	CbGbCtD
Methamphetamine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0472	0.0676	CbGbCtD
Methamphetamine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0427	0.0612	CbGbCtD
Methamphetamine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0427	0.0612	CbGbCtD
Methamphetamine—SLC18A1—vagina—acquired immunodeficiency syndrome	0.00488	0.0361	CbGeAlD
Methamphetamine—SLC6A3—nerve—acquired immunodeficiency syndrome	0.00459	0.0339	CbGeAlD
Methamphetamine—SLC18A2—blood plasma—acquired immunodeficiency syndrome	0.00459	0.0339	CbGeAlD
Methamphetamine—TAAR1—lung—acquired immunodeficiency syndrome	0.00434	0.0321	CbGeAlD
Methamphetamine—SLC18A1—nervous system—acquired immunodeficiency syndrome	0.00427	0.0316	CbGeAlD
Methamphetamine—SLC18A1—central nervous system—acquired immunodeficiency syndrome	0.00412	0.0304	CbGeAlD
Methamphetamine—TAAR1—nervous system—acquired immunodeficiency syndrome	0.00402	0.0297	CbGeAlD
Methamphetamine—MAOB—nerve—acquired immunodeficiency syndrome	0.004	0.0296	CbGeAlD
Methamphetamine—Amphetamine—CARTPT—acquired immunodeficiency syndrome	0.00388	0.377	CrCbGaD
Methamphetamine—TAAR1—central nervous system—acquired immunodeficiency syndrome	0.00387	0.0286	CbGeAlD
Methamphetamine—SLC6A2—nerve—acquired immunodeficiency syndrome	0.00371	0.0274	CbGeAlD
Methamphetamine—L-Phenylalanine—TAT—acquired immunodeficiency syndrome	0.00355	0.345	CrCbGaD
Methamphetamine—MAOA—nerve—acquired immunodeficiency syndrome	0.00341	0.0252	CbGeAlD
Methamphetamine—SLC18A1—brain—acquired immunodeficiency syndrome	0.00327	0.0241	CbGeAlD
Methamphetamine—SLC6A4—blood plasma—acquired immunodeficiency syndrome	0.00318	0.0235	CbGeAlD
Methamphetamine—SLC18A1—lymph node—acquired immunodeficiency syndrome	0.00316	0.0233	CbGeAlD
Methamphetamine—MAOB—blood plasma—acquired immunodeficiency syndrome	0.00303	0.0224	CbGeAlD
Methamphetamine—Euphoric mood—Efavirenz—acquired immunodeficiency syndrome	0.00282	0.0195	CcSEcCtD
Methamphetamine—Euphoric mood—Delavirdine—acquired immunodeficiency syndrome	0.0027	0.0186	CcSEcCtD
Methamphetamine—MAOA—blood plasma—acquired immunodeficiency syndrome	0.00258	0.0191	CbGeAlD
Methamphetamine—Euphoric mood—Ritonavir—acquired immunodeficiency syndrome	0.0025	0.0172	CcSEcCtD
Methamphetamine—Euphoric mood—Saquinavir—acquired immunodeficiency syndrome	0.0024	0.0166	CcSEcCtD
Methamphetamine—Psychotic disorder—Efavirenz—acquired immunodeficiency syndrome	0.00233	0.0161	CcSEcCtD
Methamphetamine—Tremor—Amprenavir—acquired immunodeficiency syndrome	0.00222	0.0154	CcSEcCtD
Methamphetamine—Psychotic disorder—Saquinavir—acquired immunodeficiency syndrome	0.00198	0.0137	CcSEcCtD
Methamphetamine—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.00198	0.0146	CbGeAlD
Methamphetamine—Pseudoephedrine—IL2—acquired immunodeficiency syndrome	0.00196	0.19	CrCbGaD
Methamphetamine—Erectile dysfunction—Delavirdine—acquired immunodeficiency syndrome	0.00182	0.0125	CcSEcCtD
Methamphetamine—SLC18A2—digestive system—acquired immunodeficiency syndrome	0.00177	0.0131	CbGeAlD
Methamphetamine—Agitation—Nelfinavir—acquired immunodeficiency syndrome	0.00173	0.012	CcSEcCtD
Methamphetamine—SLC18A2—blood—acquired immunodeficiency syndrome	0.00168	0.0124	CbGeAlD
Methamphetamine—Erectile dysfunction—Ritonavir—acquired immunodeficiency syndrome	0.00168	0.0116	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Amprenavir—acquired immunodeficiency syndrome	0.00167	0.0116	CcSEcCtD
Methamphetamine—Erectile dysfunction—Saquinavir—acquired immunodeficiency syndrome	0.00162	0.0112	CcSEcCtD
Methamphetamine—SLC18A2—vagina—acquired immunodeficiency syndrome	0.00156	0.0115	CbGeAlD
Methamphetamine—Dyspepsia—Didanosine—acquired immunodeficiency syndrome	0.00156	0.0107	CcSEcCtD
Methamphetamine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.00153	0.0113	CbGeAlD
Methamphetamine—Tremor—Zidovudine—acquired immunodeficiency syndrome	0.00153	0.0106	CcSEcCtD
Methamphetamine—SLC18A2—lung—acquired immunodeficiency syndrome	0.00147	0.0109	CbGeAlD
Methamphetamine—Tremor—Indinavir—acquired immunodeficiency syndrome	0.00142	0.00983	CcSEcCtD
Methamphetamine—MAOA—retina—acquired immunodeficiency syndrome	0.00141	0.0105	CbGeAlD
Methamphetamine—Agitation—Indinavir—acquired immunodeficiency syndrome	0.0014	0.00964	CcSEcCtD
Methamphetamine—Insomnia—Nelfinavir—acquired immunodeficiency syndrome	0.00139	0.00961	CcSEcCtD
Methamphetamine—Insomnia—Stavudine—acquired immunodeficiency syndrome	0.00139	0.00958	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.00137	0.00948	CcSEcCtD
Methamphetamine—Insomnia—Abacavir—acquired immunodeficiency syndrome	0.00137	0.00944	CcSEcCtD
Methamphetamine—SLC18A2—nervous system—acquired immunodeficiency syndrome	0.00137	0.0101	CbGeAlD
Methamphetamine—Dyspepsia—Nelfinavir—acquired immunodeficiency syndrome	0.00135	0.00936	CcSEcCtD
Methamphetamine—Dyspepsia—Stavudine—acquired immunodeficiency syndrome	0.00135	0.00933	CcSEcCtD
Methamphetamine—Tremor—Efavirenz—acquired immunodeficiency syndrome	0.00134	0.00929	CcSEcCtD
Methamphetamine—Palpitations—Indinavir—acquired immunodeficiency syndrome	0.00134	0.00927	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00133	0.00918	CcSEcCtD
Methamphetamine—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.00133	0.00916	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.00132	0.00915	CcSEcCtD
Methamphetamine—Agitation—Efavirenz—acquired immunodeficiency syndrome	0.00132	0.00911	CcSEcCtD
Methamphetamine—SLC18A2—central nervous system—acquired immunodeficiency syndrome	0.00131	0.00972	CbGeAlD
Methamphetamine—Constipation—Stavudine—acquired immunodeficiency syndrome	0.00131	0.00906	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.0013	0.00901	CcSEcCtD
Methamphetamine—SLC22A5—retina—acquired immunodeficiency syndrome	0.0013	0.00962	CbGeAlD
Methamphetamine—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.0013	0.00899	CcSEcCtD
Methamphetamine—Tremor—Delavirdine—acquired immunodeficiency syndrome	0.00129	0.00889	CcSEcCtD
Methamphetamine—Palpitations—Efavirenz—acquired immunodeficiency syndrome	0.00127	0.00876	CcSEcCtD
Methamphetamine—Agitation—Delavirdine—acquired immunodeficiency syndrome	0.00126	0.00872	CcSEcCtD
Methamphetamine—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.00126	0.00872	CcSEcCtD
Methamphetamine—SLC6A3—spinal cord—acquired immunodeficiency syndrome	0.00123	0.00906	CbGeAlD
Methamphetamine—SLC6A4—digestive system—acquired immunodeficiency syndrome	0.00122	0.00905	CbGeAlD
Methamphetamine—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.00122	0.00844	CcSEcCtD
Methamphetamine—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.00122	0.00842	CcSEcCtD
Methamphetamine—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00121	0.00839	CcSEcCtD
Methamphetamine—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.00121	0.00838	CcSEcCtD
Methamphetamine—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00121	0.00835	CcSEcCtD
Methamphetamine—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.00121	0.00833	CcSEcCtD
Methamphetamine—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.0012	0.00829	CcSEcCtD
Methamphetamine—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.00119	0.00822	CcSEcCtD
Methamphetamine—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.00117	0.00811	CcSEcCtD
Methamphetamine—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00117	0.00809	CcSEcCtD
Methamphetamine—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.00117	0.00806	CcSEcCtD
Methamphetamine—SLC6A4—blood—acquired immunodeficiency syndrome	0.00117	0.00862	CbGeAlD
Methamphetamine—MAOB—digestive system—acquired immunodeficiency syndrome	0.00116	0.0086	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.00115	0.00795	CcSEcCtD
Methamphetamine—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.00115	0.00791	CcSEcCtD
Methamphetamine—SLC22A5—skin of body—acquired immunodeficiency syndrome	0.00114	0.00845	CbGeAlD
Methamphetamine—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.00114	0.0079	CcSEcCtD
Methamphetamine—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.00114	0.00788	CcSEcCtD
Methamphetamine—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00113	0.00783	CcSEcCtD
Methamphetamine—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.00113	0.00781	CcSEcCtD
Methamphetamine—SLC6A4—spinal cord—acquired immunodeficiency syndrome	0.00112	0.0083	CbGeAlD
Methamphetamine—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.00112	0.00776	CcSEcCtD
Methamphetamine—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.00112	0.00775	CcSEcCtD
Methamphetamine—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.00112	0.00775	CcSEcCtD
Methamphetamine—SLC6A3—lung—acquired immunodeficiency syndrome	0.00112	0.00824	CbGeAlD
Methamphetamine—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00111	0.00769	CcSEcCtD
Methamphetamine—SLC22A3—vagina—acquired immunodeficiency syndrome	0.00111	0.00821	CbGeAlD
Methamphetamine—MAOB—blood—acquired immunodeficiency syndrome	0.00111	0.00819	CbGeAlD
Methamphetamine—Headache—Didanosine—acquired immunodeficiency syndrome	0.00111	0.00765	CcSEcCtD
Methamphetamine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.00109	0.00756	CcSEcCtD
Methamphetamine—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.00109	0.00755	CcSEcCtD
Methamphetamine—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.00109	0.00754	CcSEcCtD
Methamphetamine—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00109	0.00751	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.00107	0.0074	CcSEcCtD
Methamphetamine—MAOB—spinal cord—acquired immunodeficiency syndrome	0.00107	0.00789	CbGeAlD
Methamphetamine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.00106	0.00732	CcSEcCtD
Methamphetamine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.00106	0.00732	CcSEcCtD
Methamphetamine—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.00106	0.00732	CcSEcCtD
Methamphetamine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.00105	0.00727	CcSEcCtD
Methamphetamine—SLC22A3—lung—acquired immunodeficiency syndrome	0.00105	0.00776	CbGeAlD
Methamphetamine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00105	0.00725	CcSEcCtD
Methamphetamine—SLC18A2—brain—acquired immunodeficiency syndrome	0.00104	0.00772	CbGeAlD
Methamphetamine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00103	0.00714	CcSEcCtD
Methamphetamine—SLC6A3—nervous system—acquired immunodeficiency syndrome	0.00103	0.00764	CbGeAlD
Methamphetamine—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.00103	0.00712	CcSEcCtD
Methamphetamine—MAOB—vagina—acquired immunodeficiency syndrome	0.00103	0.0076	CbGeAlD
Methamphetamine—SLC6A4—lung—acquired immunodeficiency syndrome	0.00102	0.00756	CbGeAlD
Methamphetamine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00102	0.00703	CcSEcCtD
Methamphetamine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00101	0.00701	CcSEcCtD
Methamphetamine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.00101	0.007	CcSEcCtD
Methamphetamine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.00101	0.00699	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.00101	0.00699	CcSEcCtD
Methamphetamine—SLC18A2—lymph node—acquired immunodeficiency syndrome	0.00101	0.00745	CbGeAlD
Methamphetamine—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.001	0.00692	CcSEcCtD
Methamphetamine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000999	0.0069	CcSEcCtD
Methamphetamine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000995	0.00688	CcSEcCtD
Methamphetamine—SLC6A3—central nervous system—acquired immunodeficiency syndrome	0.000995	0.00735	CbGeAlD
Methamphetamine—MAOA—digestive system—acquired immunodeficiency syndrome	0.000993	0.00734	CbGeAlD
Methamphetamine—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000987	0.00682	CcSEcCtD
Methamphetamine—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000985	0.0068	CcSEcCtD
Methamphetamine—SLC22A3—nervous system—acquired immunodeficiency syndrome	0.000973	0.00719	CbGeAlD
Methamphetamine—MAOB—lung—acquired immunodeficiency syndrome	0.000972	0.00718	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000968	0.00669	CcSEcCtD
Methamphetamine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000964	0.00666	CcSEcCtD
Methamphetamine—Headache—Stavudine—acquired immunodeficiency syndrome	0.000961	0.00664	CcSEcCtD
Methamphetamine—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000958	0.00662	CcSEcCtD
Methamphetamine—SLC6A4—nervous system—acquired immunodeficiency syndrome	0.000947	0.007	CbGeAlD
Methamphetamine—Headache—Abacavir—acquired immunodeficiency syndrome	0.000947	0.00654	CcSEcCtD
Methamphetamine—MAOA—blood—acquired immunodeficiency syndrome	0.000946	0.00699	CbGeAlD
Methamphetamine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000937	0.00648	CcSEcCtD
Methamphetamine—SLC22A3—central nervous system—acquired immunodeficiency syndrome	0.000936	0.00692	CbGeAlD
Methamphetamine—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000931	0.00643	CcSEcCtD
Methamphetamine—SLC22A5—digestive system—acquired immunodeficiency syndrome	0.000914	0.00676	CbGeAlD
Methamphetamine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000913	0.00631	CcSEcCtD
Methamphetamine—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000912	0.0063	CcSEcCtD
Methamphetamine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000912	0.0063	CcSEcCtD
Methamphetamine—SLC6A4—central nervous system—acquired immunodeficiency syndrome	0.000911	0.00674	CbGeAlD
Methamphetamine—MAOA—spinal cord—acquired immunodeficiency syndrome	0.000911	0.00674	CbGeAlD
Methamphetamine—ADRA2C—blood—acquired immunodeficiency syndrome	0.00091	0.00672	CbGeAlD
Methamphetamine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000902	0.00623	CcSEcCtD
Methamphetamine—MAOB—nervous system—acquired immunodeficiency syndrome	0.0009	0.00665	CbGeAlD
Methamphetamine—SLC6A2—lung—acquired immunodeficiency syndrome	0.0009	0.00665	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000895	0.00618	CcSEcCtD
Methamphetamine—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.00089	0.00615	CcSEcCtD
Methamphetamine—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000886	0.00612	CcSEcCtD
Methamphetamine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000882	0.00609	CcSEcCtD
Methamphetamine—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000878	0.00607	CcSEcCtD
Methamphetamine—MAOA—vagina—acquired immunodeficiency syndrome	0.000877	0.00648	CbGeAlD
Methamphetamine—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.000876	0.00648	CbGeAlD
Methamphetamine—SLC22A5—blood—acquired immunodeficiency syndrome	0.000871	0.00644	CbGeAlD
Methamphetamine—MAOB—central nervous system—acquired immunodeficiency syndrome	0.000867	0.0064	CbGeAlD
Methamphetamine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000863	0.00596	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000861	0.00595	CcSEcCtD
Methamphetamine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000861	0.00595	CcSEcCtD
Methamphetamine—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000853	0.00589	CcSEcCtD
Methamphetamine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000848	0.00586	CcSEcCtD
Methamphetamine—ADRA2C—vagina—acquired immunodeficiency syndrome	0.000843	0.00623	CbGeAlD
Methamphetamine—SLC22A5—spinal cord—acquired immunodeficiency syndrome	0.000839	0.0062	CbGeAlD
Methamphetamine—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000838	0.00579	CcSEcCtD
Methamphetamine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000835	0.00577	CcSEcCtD
Methamphetamine—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.000833	0.00616	CbGeAlD
Methamphetamine—MAOA—lung—acquired immunodeficiency syndrome	0.000829	0.00613	CbGeAlD
Methamphetamine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000826	0.0057	CcSEcCtD
Methamphetamine—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000823	0.00569	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000822	0.00568	CcSEcCtD
Methamphetamine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00082	0.00566	CcSEcCtD
Methamphetamine—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000814	0.00562	CcSEcCtD
Methamphetamine—SLC22A5—vagina—acquired immunodeficiency syndrome	0.000808	0.00597	CbGeAlD
Methamphetamine—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.000802	0.00593	CbGeAlD
Methamphetamine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000801	0.00554	CcSEcCtD
Methamphetamine—ADRA2C—lung—acquired immunodeficiency syndrome	0.000797	0.00589	CbGeAlD
Methamphetamine—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000792	0.00548	CcSEcCtD
Methamphetamine—SLC6A3—brain—acquired immunodeficiency syndrome	0.00079	0.00584	CbGeAlD
Methamphetamine—Headache—Indinavir—acquired immunodeficiency syndrome	0.000777	0.00537	CcSEcCtD
Methamphetamine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000775	0.00535	CcSEcCtD
Methamphetamine—MAOA—nervous system—acquired immunodeficiency syndrome	0.000768	0.00568	CbGeAlD
Methamphetamine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000767	0.0053	CcSEcCtD
Methamphetamine—SLC22A5—lung—acquired immunodeficiency syndrome	0.000764	0.00564	CbGeAlD
Methamphetamine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000764	0.00528	CcSEcCtD
Methamphetamine—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000756	0.00522	CcSEcCtD
Methamphetamine—SLC22A3—brain—acquired immunodeficiency syndrome	0.000743	0.00549	CbGeAlD
Methamphetamine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000741	0.00512	CcSEcCtD
Methamphetamine—MAOA—central nervous system—acquired immunodeficiency syndrome	0.000739	0.00546	CbGeAlD
Methamphetamine—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.000738	0.00546	CbGeAlD
Methamphetamine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000735	0.00508	CcSEcCtD
Methamphetamine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000734	0.00507	CcSEcCtD
Methamphetamine—ADRA2A—blood—acquired immunodeficiency syndrome	0.000726	0.00536	CbGeAlD
Methamphetamine—SLC6A4—brain—acquired immunodeficiency syndrome	0.000724	0.00535	CbGeAlD
Methamphetamine—SLC22A3—lymph node—acquired immunodeficiency syndrome	0.000718	0.00531	CbGeAlD
Methamphetamine—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.000711	0.00525	CbGeAlD
Methamphetamine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000709	0.0049	CcSEcCtD
Methamphetamine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000702	0.00485	CcSEcCtD
Methamphetamine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000701	0.00484	CcSEcCtD
Methamphetamine—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.000699	0.00517	CbGeAlD
Methamphetamine—MAOB—brain—acquired immunodeficiency syndrome	0.000688	0.00508	CbGeAlD
Methamphetamine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000685	0.00474	CcSEcCtD
Methamphetamine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000683	0.00472	CcSEcCtD
Methamphetamine—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000673	0.00497	CbGeAlD
Methamphetamine—MAOB—lymph node—acquired immunodeficiency syndrome	0.000665	0.00491	CbGeAlD
Methamphetamine—Pseudoephedrine—TNF—acquired immunodeficiency syndrome	0.000661	0.0642	CrCbGaD
Methamphetamine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00066	0.00456	CcSEcCtD
Methamphetamine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000651	0.0045	CcSEcCtD
Methamphetamine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000649	0.00449	CcSEcCtD
Methamphetamine—SLC6A2—brain—acquired immunodeficiency syndrome	0.000637	0.00471	CbGeAlD
Methamphetamine—ADRA2A—lung—acquired immunodeficiency syndrome	0.000636	0.0047	CbGeAlD
Methamphetamine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000629	0.00435	CcSEcCtD
Methamphetamine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000625	0.00432	CcSEcCtD
Methamphetamine—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.000616	0.00455	CbGeAlD
Methamphetamine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000596	0.00412	CcSEcCtD
Methamphetamine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.00059	0.00436	CbGeAlD
Methamphetamine—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000589	0.00435	CbGeAlD
Methamphetamine—MAOA—brain—acquired immunodeficiency syndrome	0.000587	0.00434	CbGeAlD
Methamphetamine—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000567	0.00419	CbGeAlD
Methamphetamine—MAOA—lymph node—acquired immunodeficiency syndrome	0.000567	0.00419	CbGeAlD
Methamphetamine—ADRA2C—brain—acquired immunodeficiency syndrome	0.000564	0.00417	CbGeAlD
Methamphetamine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000562	0.00415	CbGeAlD
Methamphetamine—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.000545	0.00403	CbGeAlD
Methamphetamine—SLC22A5—brain—acquired immunodeficiency syndrome	0.000541	0.004	CbGeAlD
Methamphetamine—SLC22A5—lymph node—acquired immunodeficiency syndrome	0.000522	0.00386	CbGeAlD
Methamphetamine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000456	0.00337	CbGeAlD
Methamphetamine—ADRA2A—brain—acquired immunodeficiency syndrome	0.00045	0.00333	CbGeAlD
Methamphetamine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000439	0.00325	CbGeAlD
Methamphetamine—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.000435	0.00322	CbGeAlD
Methamphetamine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000349	0.00258	CbGeAlD
Methamphetamine—Nateglinide—ALB—acquired immunodeficiency syndrome	0.000244	0.0237	CrCbGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	6.69e-05	0.006	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	6.49e-05	0.00582	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	6.46e-05	0.0058	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	6.25e-05	0.00561	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	6.21e-05	0.00557	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	6.21e-05	0.00557	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.08e-05	0.00545	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.08e-05	0.00545	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.87e-05	0.00527	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	5.84e-05	0.00524	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	5.63e-05	0.00505	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.61e-05	0.00504	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	5.61e-05	0.00504	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.52e-05	0.00495	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.52e-05	0.00495	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—TAT—acquired immunodeficiency syndrome	5.44e-05	0.00488	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	5.26e-05	0.00472	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	5.2e-05	0.00466	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	5.09e-05	0.00457	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	5.07e-05	0.00455	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	4.89e-05	0.00439	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	4.89e-05	0.00439	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	4.85e-05	0.00436	CbGpPWpGaD
Methamphetamine—SLC18A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	4.85e-05	0.00435	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.82e-05	0.00433	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.77e-05	0.00428	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	4.76e-05	0.00427	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.62e-05	0.00415	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—AGPS—acquired immunodeficiency syndrome	4.62e-05	0.00415	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—TAT—acquired immunodeficiency syndrome	4.6e-05	0.00413	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.57e-05	0.0041	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	4.56e-05	0.0041	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	4.56e-05	0.0041	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.55e-05	0.00409	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.53e-05	0.00407	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.51e-05	0.00404	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.46e-05	0.004	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	4.27e-05	0.00383	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	4.27e-05	0.00383	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	4.24e-05	0.0038	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.2e-05	0.00377	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.16e-05	0.00374	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.13e-05	0.00371	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	4.13e-05	0.00371	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	3.94e-05	0.00354	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—AGPS—acquired immunodeficiency syndrome	3.91e-05	0.00351	CbGpPWpGaD
Methamphetamine—SLC18A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.9e-05	0.0035	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.89e-05	0.00349	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.89e-05	0.00349	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	3.86e-05	0.00347	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.86e-05	0.00346	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	3.85e-05	0.00345	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.83e-05	0.00344	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.78e-05	0.00339	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.72e-05	0.00334	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	3.71e-05	0.00333	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	3.71e-05	0.00333	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	3.66e-05	0.00328	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.63e-05	0.00326	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.63e-05	0.00326	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	3.62e-05	0.00325	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	3.59e-05	0.00322	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.48e-05	0.00312	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.47e-05	0.00312	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.47e-05	0.00311	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	3.47e-05	0.00311	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	3.44e-05	0.00309	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—TAT—acquired immunodeficiency syndrome	3.41e-05	0.00306	CbGpPWpGaD
Methamphetamine—SLC22A3—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.37e-05	0.00302	CbGpPWpGaD
Methamphetamine—SLC22A5—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	3.36e-05	0.00301	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	3.35e-05	0.00301	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.26e-05	0.00293	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.26e-05	0.00293	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.25e-05	0.00292	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.15e-05	0.00282	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.14e-05	0.00281	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	3.13e-05	0.00281	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.11e-05	0.00279	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.96e-05	0.00266	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.96e-05	0.00266	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.96e-05	0.00265	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	2.95e-05	0.00265	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	2.95e-05	0.00265	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.94e-05	0.00264	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	2.92e-05	0.00262	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.9e-05	0.00261	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—AGPS—acquired immunodeficiency syndrome	2.9e-05	0.0026	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.89e-05	0.00259	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	2.82e-05	0.00253	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.82e-05	0.00253	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—TAT—acquired immunodeficiency syndrome	2.81e-05	0.00252	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.76e-05	0.00248	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.76e-05	0.00248	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.76e-05	0.00248	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	2.71e-05	0.00243	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.7e-05	0.00242	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.66e-05	0.00239	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	2.64e-05	0.00237	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.63e-05	0.00236	CbGpPWpGaD
Methamphetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	2.62e-05	0.00235	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.61e-05	0.00235	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	2.54e-05	0.00228	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—IFNA1—acquired immunodeficiency syndrome	2.53e-05	0.00227	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	2.51e-05	0.00225	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.49e-05	0.00223	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.48e-05	0.00223	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.44e-05	0.00219	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.44e-05	0.00219	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.41e-05	0.00216	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.39e-05	0.00214	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—AGPS—acquired immunodeficiency syndrome	2.39e-05	0.00214	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—IFNA1—acquired immunodeficiency syndrome	2.37e-05	0.00212	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.36e-05	0.00212	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	2.34e-05	0.0021	CbGpPWpGaD
Methamphetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	2.32e-05	0.00208	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—TAT—acquired immunodeficiency syndrome	2.28e-05	0.00205	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.25e-05	0.00202	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.24e-05	0.00201	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.24e-05	0.00201	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.24e-05	0.00201	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.23e-05	0.002	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	2.22e-05	0.00199	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.19e-05	0.00197	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.19e-05	0.00196	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.19e-05	0.00196	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.14e-05	0.00192	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.1e-05	0.00189	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	2.03e-05	0.00182	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.03e-05	0.00182	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.02e-05	0.00181	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.98e-05	0.00178	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.98e-05	0.00178	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.98e-05	0.00178	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—AGPS—acquired immunodeficiency syndrome	1.94e-05	0.00174	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.92e-05	0.00173	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	1.9e-05	0.00171	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.9e-05	0.0017	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.89e-05	0.0017	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.85e-05	0.00166	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	1.79e-05	0.00161	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.79e-05	0.0016	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.79e-05	0.0016	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.78e-05	0.0016	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.71e-05	0.00154	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.71e-05	0.00153	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.71e-05	0.00153	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.71e-05	0.00153	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.71e-05	0.00153	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.67e-05	0.0015	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.67e-05	0.0015	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.67e-05	0.0015	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.66e-05	0.00149	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.61e-05	0.00145	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.59e-05	0.00143	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.59e-05	0.00143	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.56e-05	0.0014	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.56e-05	0.0014	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.54e-05	0.00139	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.54e-05	0.00138	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.54e-05	0.00138	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.52e-05	0.00136	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.52e-05	0.00136	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.51e-05	0.00135	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.5e-05	0.00135	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.49e-05	0.00133	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.44e-05	0.00129	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.42e-05	0.00127	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.42e-05	0.00127	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.35e-05	0.00122	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.35e-05	0.00121	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.33e-05	0.0012	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.3e-05	0.00116	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.3e-05	0.00116	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—ALB—acquired immunodeficiency syndrome	1.29e-05	0.00116	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.29e-05	0.00116	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.28e-05	0.00115	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.27e-05	0.00114	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.27e-05	0.00114	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.27e-05	0.00114	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.26e-05	0.00113	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.25e-05	0.00112	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.23e-05	0.0011	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—ALB—acquired immunodeficiency syndrome	1.21e-05	0.00108	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.19e-05	0.00107	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.18e-05	0.00106	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.17e-05	0.00105	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.17e-05	0.00105	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.16e-05	0.00104	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.15e-05	0.00103	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.15e-05	0.00103	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.15e-05	0.00103	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.14e-05	0.00102	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.08e-05	0.000968	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.07e-05	0.000961	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.06e-05	0.000954	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.05e-05	0.000947	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—IL2—acquired immunodeficiency syndrome	1.05e-05	0.00094	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.04e-05	0.000934	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.85e-06	0.000884	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	9.8e-06	0.00088	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—IL2—acquired immunodeficiency syndrome	9.79e-06	0.000878	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.72e-06	0.000872	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	9.65e-06	0.000866	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.54e-06	0.000856	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	9.51e-06	0.000853	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—ALB—acquired immunodeficiency syndrome	9.48e-06	0.000851	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.97e-06	0.000805	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.97e-06	0.000805	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.91e-06	0.0008	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.76e-06	0.000786	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	8.69e-06	0.00078	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.63e-06	0.000775	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.38e-06	0.000752	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.38e-06	0.000752	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—ALB—acquired immunodeficiency syndrome	8.02e-06	0.00072	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8e-06	0.000718	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	7.95e-06	0.000713	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.9e-06	0.000709	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.59e-06	0.000681	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.24e-06	0.00065	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.82e-06	0.000612	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.81e-06	0.000611	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.81e-06	0.000611	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.72e-06	0.000603	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.62e-06	0.000594	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.37e-06	0.000572	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.28e-06	0.000563	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.18e-06	0.000555	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.15e-06	0.000552	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.01e-06	0.00054	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—ALB—acquired immunodeficiency syndrome	5.95e-06	0.000534	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.74e-06	0.000515	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.62e-06	0.000504	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.18e-06	0.000465	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.1e-06	0.000458	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.02e-06	0.000451	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	4.89e-06	0.000439	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.66e-06	0.000419	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.56e-06	0.000409	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	3.97e-06	0.000357	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.55e-06	0.000319	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.53e-06	0.000317	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.32e-06	0.000298	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.3e-06	0.000296	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.69e-06	0.000242	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.68e-06	0.000241	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	2.59e-06	0.000232	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.09e-06	0.000187	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.95e-06	0.000175	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.58e-06	0.000142	CbGpPWpGaD
